Tag Archives: monotherapy

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2

Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2

Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding with no concomitant increase in major adverse cardiovascular events (MACE). Traditionally, the therapeutic window was limited to monotherapy with P2Y12 inhibitors during the first year and there are few data on short DAPT followed by long term monotherapy

indicación de tratamiento con estatinas

Anti-Lipid Therapy in PCI Patients: Monotherapy with Statins or Combination?

According to several studies, in patients with high-risk atherosclerotic disease, such as those affected by coronary artery disease, achieving target LDL levels through high-intensity statin therapy has been shown to lead to a significant reduction in long-term cardiovascular events. Therefore, the management of dyslipidemia has become a fundamental pillar of secondary prevention. However, reaching such

ESC 2023

ESC 2023 | Extended Monotherapy with Clopidogrel vs. DAPT in High-Risk Patients

An increasing number of patients currently present both an elevated ischemic risk and hemorrhagic risk. This means that the selection of the optimal antiplatelet treatment is a clinical challenge. Several studies have shown that P2Y12 monotherapy after minimum dual antiplatelet therapy (DAPT) is a novel strategy to reduce bleeding risk without increasing ischemic risk. Furthermore,

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

TICO: Age Impacts the Effect of Antiplatelet Monotherapy

The higher the age, the greater the benefit of ticagrelor monotherapy vs. dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome. This post hoc sub-analysis of the TICO study goes along the same lines as the TWILIGHT study (which we recently discussed), given that age is the most common reason for considering that a

Esquema corto y monoterapia, una práctica llena de evidencia

Post-PCI Ticagrelor Monotherapy in High-Risk Bleeding

In patients at high risk of bleeding undergoing coronary PCI and after completing 3-month DAPT with no events, you may discontinue aspirin and follow up with ticagrelor monotherapy. This will significantly reduce bleeding without increasing ischemic events.  With this strategy, the greater the risk of bleeding, the greater the absolute reduction of bleeding. Patients at

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

HOST-EXAM: The Study that Challenges Aspirin as Long-Term Antiplatelet Therapy

The HOST-EXAM study (which was prospective, randomized, and open-label, with the participation of 37 Korean sites) was specifically designed to determine the role of aspirin as the long-term antiplatelet therapy of choice after angioplasty with current drug-eluting stents. To this end, the study compared aspirin head-to-head with clopidogrel. Over the course of four years, 5438 patients (mean

Doctor con tabletas de aspirinas

The Role of Aspirin after the TWILIGHT-ACS

This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT) in patients with acute coronary syndrome (ACS). This benefit consists of a significant bleeding reduction (3.6% vs. 7.6%, P < 0.001), without compromising ischemic events (4.3% vs. 4.4%, P = 0.84). The latter, however, could be seen as

ACC 2021 | HOST-EXAM: Clopidogrel vs AAS como monoterapia post DAPT en las angioplastias

ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA). This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet. Researchers followed patients for 2 years and observed

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Angioplasty in Aspirin-Free Stable Patients with Prasugrel: Innovation Continues

Potent P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, have been tested mainly in a setting of acute coronary syndromes. There is little evidence on stable patients, particularly for prasugrel. Designing a study with that purpose seemed challenging enough, but adding aspirin discontinuation in patients without a particularly high bleeding risk took this research to

TCT 2020 | Ticagrelor Monotherapy After ST-Segment Elevation Infarction

Ticagrelor monotherapy after 3 months of dual antiplatelet therapy in patients who experienced ST-segment elevation infarction significantly reduces major bleeding without increasing ischemic risk. This pre-specified analysis of the TICO study shows that ticagrelor monotherapy is safe even in patients with higher ischemic risk. Interrupting aspirin use after 3 months of dual antiplatelet therapy and continuing treatment